Get the Stockscreener App
12.09
0.25%
0.03
Trevi Therapeutics Inc stock is traded at $12.09, with a volume of 683.43K.
It is up +0.25% in the last 24 hours and down -19.61% over the past month.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
See More
Previous Close:
$12.06
Open:
$12.06
24h Volume:
683.43K
Relative Volume:
0.18
Market Cap:
$1.72B
Revenue:
Net Income/Loss:
$-45.61M
P/E Ratio:
-37.37
EPS:
-0.3235
Net Cash Flow:
$-45.40M
1W Performance:
-5.73%
1M Performance:
-19.61%
6M Performance:
-15.28%
1Y Performance:
+13.84%
1-Day Range:
$12.00
$12.38
1-Week Range:
$12.00
$13.46
52-Week Range:
$9.28
$20.22
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Name
Trevi Therapeutics Inc
Sector
Industry
Phone
203-304-2499
Address
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
12.09 | 1.72B | 0 | -45.61M | -45.40M | -0.3235 |
VRTX
Vertex Pharmaceuticals Inc
|
509.72 | 129.19B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.78 | 94.93B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.11 | 82.48B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.35 | 53.35B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.37 | 42.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-26 | Initiated | BMO Capital Markets | Outperform |
| Nov-13-25 | Initiated | Leerink Partners | Outperform |
| Aug-21-25 | Initiated | Morgan Stanley | Overweight |
| Jul-01-25 | Initiated | Cantor Fitzgerald | Overweight |
| May-28-25 | Initiated | H.C. Wainwright | Buy |
| Mar-10-25 | Reiterated | Needham | Buy |
| Mar-10-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-12-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-30-24 | Initiated | Raymond James | Outperform |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-12-23 | Initiated | B. Riley Securities | Buy |
| Nov-22-22 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | BMO Capital Markets | Outperform |
| Jun-03-19 | Initiated | Needham | Buy |
| Jun-03-19 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | Stifel | Buy |
View All
Trevi Therapeutics Inc Stock (TRVI) Latest News
Trevi Therapeutics (TRVI) director sells 39,473 shares under trading plan - Stock Titan
Trevi Therapeutics stock trades in a data vacuum as Haduvio moves toward Phase 3 - AD HOC NEWS
Trevi Therapeutics Insider Sold Shares Worth $595,806, According to a Recent SEC Filing - Yahoo Finance
Director at Trevi Therapeutics (NASDAQ: TRVI) plans share sale after option exercise - Stock Titan
Trevi Therapeutics at cantor global healthcare conference: central cough bet By Investing.com - Investing.com Canada
Trevi Therapeutics at cantor global healthcare conference: central cough bet By Investing.com - Investing.com UK
BMO initiates coverage on Trevi Therapeutics at $36 - scanx.trade
Trevi Therapeutics (TRVI) Edges Lower 1.07% as Shares Consolidate Between Key Support and ResistanceETF Outflow Streak - siam.in
Trevi Therapeutics (TRVI) Edges Lower 1.07% as Shares Consolidate Between Key Support and ResistanceTWAP Entry - dars.gov.et
Trevi Therapeutics (TRVI) Stock Trades At A Premium To Fair Value - Yahoo Finance
BEAM Stock Price and Chart — NASDAQ:BEAM - TradingView
Trevi Therapeutics Inc (TRVI) Peer Comparison – Compare with Others - Value Research
Trevi Therapeutics to Present at Multiple Healthcare and IPF Conferences in September 2026 - Quiver Quantitative
Trevi Therapeutics to Participate in Upcoming September Conferences - Yahoo Finance
Trevi Therapeutics Inc (TRVI) Key Financial Ratios – Valuation, Profitability & More - Value Research
EX-99.1 - SEC.gov
Trevi Therapeutics Inc (TRVI) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026 - GlobeNewswire
Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform (NASDAQ:TRVI) - Seeking Alpha
$Trevi Therapeutics (TRVI.US)$ lets punch through that BOLL band - Moomoo
Walleye Capital LLC Purchases Shares of 241,987 Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics Stock Price Forecast. Should You Buy TRVI? - StockInvest.us
TRVI Maintained by Jones Trading -- Price Target Raised to $28.0 - GuruFocus
JonesTrading Forecasts Strong Price Appreciation for Trevi Therapeutics (NASDAQ:TRVI) Stock - MarketBeat
Does Wider Losses And New US$149.2m Shelf Offering Change The Bull Case For Trevi (TRVI)? - simplywall.st
Does Wider Losses And New US$149.2m Shelf Offering Change The Bull Case For Trevi (TRVI)? - simplywall.st
Does Wider Losses And New US$149.2m Shelf Offering Change The Bull Case For Trevi (TRVI)? - simplywall.st
Does Wider Losses And New US$149.2m Shelf Offering Change The Bull Case For Trevi (TRVI)? - simplywall.st
HC Wainwright Issues Pessimistic Estimate for TRVI Earnings - MarketBeat
Sei Investments Co. Has $933,000 Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
What is HC Wainwright's Forecast for TRVI FY2030 Earnings? - MarketBeat
H.C. Wainwright Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $24 - Moomoo
Trevi Therapeutics (TRVI) Short Interest & Short Float | Updated Aug 2026 $TRVI - MarketBeat
Morgan Stanley Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $23 - Moomoo
1,525,314 Shares in Trevi Therapeutics, Inc. $TRVI Acquired by Assenagon Asset Management S.A. - MarketBeat
Companies Like Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Invest In Growth - moomoo.com
A Quick Look at Today's Ratings for Trevi Therapeutics(TRVI.US), With a Forecast Between $23 to $40 - Moomoo
Raymond James Sticks to Its Buy Rating for Trevi Therapeutics (TRVI) - The Globe and Mail
Trevi Therapeutics (TRVI) Receives a New Rating from B. Riley Securities - The Globe and Mail
Q2 2026 Trevi Therapeutics Inc Earnings Call Transcript - GuruFocus
Oppenheimer Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $25 - Moomoo
Morgan Stanley Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $23 - Moomoo
Trevi Therapeutics (NASDAQ:TRVI) Announces Earnings Results, Hits Estimates - marketbeat.com
Trevi Therapeutics Q2 Earnings Call Highlights - MarketBeat
Trevi Therapeutics Q2 Earnings Call Highlights - TradingView
Trevi Therapeutics, Inc. Stock 12‑Month Price Target Raised to $29.17, Implies 58% Upside - TradingView
Trevi Therapeutics Inc (TRVI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TRVI Maintains Rating by Oppenheimer -- Price Target Raised to $25.00 - GuruFocus
TRVI Maintains Overweight Rating -- Price Target Raised to $30 b - GuruFocus
Oppenheimer Adjusts Trevi Therapeutics PT to $25 From $24, Maintains Outperform Rating - marketscreener.com
Trevi Therapeutics Inc Stock (TRVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Trevi Therapeutics Inc Stock (TRVI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Heffernan Michael Thomas | Director |
Sep 15 '26 |
Sale |
15.09 |
39,473 |
595,806 |
6,351 |
| MICHAEL HEFFERNAN | Director |
Sep 15 '26 |
Proposed Sale |
15.89 |
39,473 |
627,226 |
0 |
| Galletta Christopher | See Remarks |
Dec 02 '25 |
Option Exercise |
0.51 |
4,225 |
2,159 |
26,095 |
| Delfini Lisa | Officer |
Oct 07 '25 |
Proposed Sale |
9.50 |
108,650 |
1,032,175 |
0 |
| Delfini Lisa | Officer |
Oct 03 '25 |
Proposed Sale |
9.67 |
40,000 |
386,716 |
0 |
4.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):